Aristides Capital LLC Boosts Stock Holdings in Kamada Ltd. (NASDAQ:KMDA)

Aristides Capital LLC boosted its holdings in shares of Kamada Ltd. (NASDAQ:KMDA) by 12.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 63,485 shares of the biotechnology company’s stock after purchasing an additional 6,850 shares during the quarter. Aristides Capital LLC’s holdings in Kamada were worth $387,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Public Employees Retirement System of Ohio acquired a new position in Kamada during the third quarter worth $77,000. JPMorgan Chase & Co. acquired a new stake in shares of Kamada during the 4th quarter worth about $67,000. Finally, Geode Capital Management LLC increased its position in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company’s stock valued at $178,000 after acquiring an additional 1,549 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors and hedge funds.

Kamada Trading Down 4.6 %

Kamada stock opened at $5.99 on Friday. The stock has a 50 day moving average of $7.09 and a two-hundred day moving average of $6.35. Kamada Ltd. has a twelve month low of $4.74 and a twelve month high of $9.16. The stock has a market capitalization of $344.31 million, a price-to-earnings ratio of 21.39, a PEG ratio of 0.97 and a beta of 0.97.

Kamada Announces Dividend

The business also recently disclosed a — dividend, which will be paid on Monday, April 7th. Investors of record on Monday, March 17th will be issued a dividend of $0.20 per share. The ex-dividend date is Monday, March 17th.

Wall Street Analysts Forecast Growth

KMDA has been the subject of a number of research reports. Benchmark assumed coverage on Kamada in a research note on Friday, March 21st. They issued a “buy” rating and a $15.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $11.00 price objective on shares of Kamada in a research note on Thursday, March 6th. Finally, StockNews.com lowered Kamada from a “strong-buy” rating to a “buy” rating in a report on Tuesday, March 25th.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.